ReviewDrugs2001
Fluoroquinolones: place in ocular therapy.
Review in Drugs, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 185 citations in OpenAlex.
- Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.Drugs in R&D · 2017Trial
- Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery.Antimicrobial agents and chemotherapy · 2005Trial
- Stimuli-Responsive Crosslinked Chitosan/PVP/PEG Hydrogel Networks for Targeted Drug Delivery and Antimicrobial Performance.Analytical science advances · 2026Article
- Repurposing fluoroquinolones as cancer chemosensitizers: a way to overcome cancer therapeutic bottleneck.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Bilateral endogenous fungal endophthalmitis following elective surgical abortion: a single center case series.Journal of ophthalmic inflammation and infection · 2025Article
- Evaluation of moxifloxacin penetration into corneal lenticules extracted during SMILE surgery.International ophthalmology · 2025Article
- Increased risk of pigmentary degeneration of the iris and pigmentary glaucoma with fluoroquinolone antibiotics.Eye (London, England) · 2024Article
- Microbiological isolates and associated complications of dacryocystitis and canaliculitis in a prominent tertiary ophthalmic teaching hospital in northern China.BMC ophthalmology · 2024Article
- Thermosensitive Polyhedral Oligomeric Silsesquioxane Hybrid Hydrogel Enhances the Antibacterial Efficiency of Erythromycin in Bacterial Keratitis.Biomaterials research · 2024Article
- Oral administration of S-nitroso-L-glutathione (GSNO) provides anti-inflammatory and cytoprotective effects during ocular bacterial infections.Cellular and molecular life sciences : CMLS · 2023Article
- Sorangicin A Is Active againstAntibiotics (Basel, Switzerland) · 2023Article
- Evaluation of delaying effects of different short-term dosage regimens of topical ciprofloxacin on corneal ulcer healing in an avian model.Veterinary medicine and science · 2023Article
- Penetration of Enrofloxacin in Aqueous Humour of Avian Eyes.Veterinary sciences · 2022Article
- The Relationship between Ciprofloxacin Resistance and Genotypic Changes inPathogens (Basel, Switzerland) · 2022Article
- Potential new fluoroquinolone treatments for suspected bacterial keratitis.BMJ open ophthalmology · 2022Review
- Impacts of Bacteriostatic and Bactericidal Antibiotics on the Mitochondria of the Age-Related Macular Degeneration Cybrid Cell Lines.Biomolecules · 2022Article
- Weaning of septic patients from the ventilator in the intensive care unit by attention approach to common antibiotic regimens.Journal of family medicine and primary care · 2022Article
- Neonatal Endogenous Endophthalmitis: A Case Report.Cureus · 2022Article
- Development of topical chitosan/ β-glycerophosphate-based hydrogel loaded with levofloxacin in the treatment of keratitis: AnHeliyon · 2022Article
- Effects of fluoroquinolones and tetracyclines on mitochondria of human retinal MIO-M1 cells.Experimental eye research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fluoroquinolones have become widely used antibacterial agents in the treatment of ocular infections, with topical, intravitreal and systemic routes of administration being used. In general, fluoroquinolones (such as ciprofloxacin, ofloxacin, lomefloxacin and norfloxacin) have good activity against gram-negative and gram-positive bacteria. Therapeutic concentrations are achieved in the cornea after topical administration so that the fluoroqinolones have largely replaced combination therapy for the treatment of bacterial keratitis. However, a second line agent is needed when resistance is likely, such as in disease caused by streptococcal species. Reversal of resistance to quinolones may not occur with withdrawal of the antibacterial. This stresses the importance of prudent prescribing to reduce the occurrence of resistance to quinolones. When used in therapeutic topical dosages, corneal toxicity does not occur. Similarly, retinal toxicity is not seen when fluoroquinolones are used at therapeutic dosages, systemically or topically. Corneal precipitation occurs, particularly with ciprofloxacin and to a lesser extent norfloxacin, but does not appear to interfere with healing. In the treatment of endophthalmitis there is reasonable penetration of systemic fluoroquinolones into the vitreous but sufficiently high concentrations to reach the minimum inhibitory concentration for 90% of isolates (MIC90) of all important micro-organisms may not be guaranteed. Systemic administration may be useful for prophylaxis after ocular trauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.